November 2022 - What's New in Opioids, Mental Health, HIV, and STIs (Day 1 of 2)
Join Us for a Virtual Conference provided in collaboration by:
The STD/HIV Prevention Training Center, MidAtlantic AETC, The Danya Institute-Central East Addiction Technology Transfer Center, Virginia Department of Health, and Global Tuberculosis Institute.
Important note: To receive continuing education credit, you must attend both days in their entirety and complete all required evaluations within the stated timeframe.
This conference will focus on the integration efforts that support a collaborative healthcare approach. Current medical updates in services for STIs, HIV, hepatitis, tuberculosis, and substance use disorder will be discussed.
After completing this conference, the learner should
be able to:
1. State current practice in the care and treatment of STIs, HIV, TB, and hepatitis
2. Explain how to screen clients for substance use disorder issues
3. Identify Population at risk for HIV/STIs/Mental Health and substance use disorder
4. Demonstrate effective team skills by sharing information effectively, listening and responding to feedback from others, and using simple communication
Important note: To receive continuing education credit, you must attend both days in their entirety and complete all required evaluations and post tests, within the stated timeframe.
CME: The Centers for Disease Control and Prevention designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits TM. Physicians should only claim
the credit commensurate with the extent of their participation in the activity.
CNE: The Centers for Disease Control and Prevention designates this activity for 6.2 nursing contact hours.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.6 CEU’s for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education
contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 6.5 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. Continuing Competency credits available are 6.5. CDC provider number 98614.
For Certified Public Health Professionals (CPH) The Centers for Disease Control and Prevention is a preapproved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 7.0 CPH recertification credits for this program.
To register for Day 2: Please click the link on the right side of this page.
Please contact the MidAtlantic AETC at email@example.com with questions or concerns.
In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.
CDC, our planners, and presenters wish to disclose they have no financial relationship(s) with ineligible companies with the exception of Dr. Dillingham and she wishes to disclose that she is a consultant for Warm Health Technology, Inc. Also Dr. Fraimow would like to disclose that he is a researcher/consultant for Shionogi Inc.
All of the relevant financial relationships listed for these individuals have been mitigated.
Content will not include any discussion of the unlabeled use of a product or a product under investigational use .
CDC did not accept commercial support for this continuing education activity.
This course has been designed for physicians, physician assistants, clinicians, nurses, nurse practitioners, counselors, social workers, educators, case managers, and intervention specialists working with people with substance use disorder, TB/STI/HIV agencies and other programs.
Register for Day 2:
A variety of the listed topics will be discussed at this event.
- HIV Transmission Risk Assessment
- Medication-assisted therapy for substance use disorders (i.e. buprenorphine, methadone, and/or naltrexone)
- Mental health disorders
- Sexually transmitted infections
- Substance use disorders
- Opioid use disorder
- Stigma or discrimination